The proposed research will concentrate on the mechanism of action of hormones on hepatic gluconeogenesis and glycolysis. The hypothesis which will be tested is as follows: Hormonal control of hepatic gluconeogenesis and glycolysis is mediated by cAMP-dependent and/or independent phosphorylation of several cytoplasmic enzymes involved in F6P/F1,6-P2 and PEP/Pyruvate substrate cycles and of the enzyme(s) involved in the synthesis and degradation of the recently discovered sugar diphosphate, fructose 2, 6-bisphosphate. Research will continue to focus on L-type pyruvate kinase, fructose 1, 6-bisphosphatase, 6-phosphofructo 1-kinase, and two recently discovered enzymes 6-phosphofructo 2-kinase and fructose 2,6-bisphosphatase. 6-Phosphofructo 2-kinase/fructose 2,6-bisphosphatase will be purified to homogeneity and their physical and kinetic properties studied. In vitro phosphorylation of these enzymes catalyzed by the cAMP-dependent protein kinase and perhaps by other kinases will be characterized. The effect of glucagon, insulin, catecholamines and various substrates on 32P incorporation into 6-phosphofructo 2-kinase/fructose 2,6-bisphosphatase in isolated hepatocytes will be investigated using immunological methods to isolate the enzymes. The phosphorylation state of the enzymes in intact cells will be correlated with enzyme activity measured in hepatocyte extracts and with cAMP levels. The regulation of activity of these enzymes will be studied in various dietary and hormonal states both in vivo and in isolated liver systems. We will also investigate the modulation of fructose 2, 6-bisphosphate levels in vivo and in isolated hepatocytes and assess the importance of this regulation vis a vis hepatic glycolysis and gluconeogenesis. In order to achieve this latter goal we will employ a conscious, intact dog model where endocrine pancreatic function can be controlled by virtue of a """"""""pancreatic clamp"""""""" technique and substrate levels can be controlled by supplementation techniques. The interaction of fructose 2, 6-bisphosphate and other allosteric effectors with 6-phosphofructo 1-kinase, fructose 1,6-bisphosphatase, pyruvate kinase, and 6-phosphofructo 2-kinase will also be investigated. Finally, the effect of phosphorylation on the kinetic and physical properties of these enzymes will be assessed by a number of techniques.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK038354-02
Application #
3237706
Study Section
Metabolism Study Section (MET)
Project Start
1986-06-01
Project End
1988-07-31
Budget Start
1987-06-01
Budget End
1988-07-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
State University New York Stony Brook
Department
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Pedersen, Kim B; Zhang, Pili; Doumen, Chris et al. (2007) The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regions. Am J Physiol Endocrinol Metab 292:E788-801
Wu, Chaodong; Khan, Salmaan A; Peng, Li-Jen et al. (2006) Roles for fructose-2,6-bisphosphate in the control of fuel metabolism: beyond its allosteric effects on glycolytic and gluconeogenic enzymes. Adv Enzyme Regul 46:72-88
Wu, Chaodong; Khan, Salmaan A; Peng, Li-Jen et al. (2006) Perturbation of glucose flux in the liver by decreasing F26P2 levels causes hepatic insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab 291:E536-43
Wu, Chaodong; Kang, Johnthomas E; Peng, Li-Jen et al. (2005) Enhancing hepatic glycolysis reduces obesity: differential effects on lipogenesis depend on site of glycolytic modulation. Cell Metab 2:131-40
Wu, Chaodong; Okar, David A; Kang, Johnthomas et al. (2005) Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr Drug Targets Immune Endocr Metabol Disord 5:51-9
Baar, Rachel A; Dingfelder, Carlus S; Smith, Lisa A et al. (2005) Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice. Am J Physiol Endocrinol Metab 288:E187-93
Massa, Laura; Baltrusch, Simone; Okar, David A et al. (2004) Interaction of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) with glucokinase activates glucose phosphorylation and glucose metabolism in insulin-producing cells. Diabetes 53:1020-9
Donthi, Rajakumar V; Ye, Gang; Wu, Chaodong et al. (2004) Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. J Biol Chem 279:48085-90
Wu, Chaodong; Okar, David A; Stoeckman, Angela K et al. (2004) A potential role for fructose-2,6-bisphosphate in the stimulation of hepatic glucokinase gene expression. Endocrinology 145:650-8
Okar, David A; Wu, Chaodong; Lange, Alex J (2004) Regulation of the regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Adv Enzyme Regul 44:123-54

Showing the most recent 10 out of 73 publications